{"url_path":"/sec/cik-0001178879/8-k/2026-04-27/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1178879/0001140361-26-016968-index.html","accession_number":"0001140361-26-016968","cik":"0001178879","ticker":null,"issuer_name":"AMICUS THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1178879/0001140361-26-016968-index.html","primary_entity_key":"0001178879","primary_entity_name":"AMICUS THERAPEUTICS, INC."},"word_count":197,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n \n\n(d)\n\nExhibits.\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n \n\n \n\n[2.1](https://www.sec.gov/Archives/edgar/data/1178879/000114036125046134/ef20061157_ex2-1.htm)\n\nAgreement and Plan of Merger, dated as of December 19, 2025, by and among Amicus Therapeutics, Inc., BioMarin Pharmaceutical Inc., and Lynx Merger Sub 1,\nInc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 19, 2025).*\n\n[3.1](ef20071351_ex3-1.htm)\n\nAmended and Restated Certificate of Incorporation of Amicus Therapeutics, Inc.\n\n[3.2](ef20071351_ex3-2.htm)\n\nAmended and Restated Bylaws of Amicus Therapeutics, Inc.\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n*\n\nSchedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the\nomitted schedules upon request by the SEC; provided, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules so furnished.\n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\nAmicus Therapeutics, Inc.\n\n \n\n \n\n \n\nDated: April 27, 2026\n\nBy:\n\n/s/ G. Eric Davis\n\n \n\n \n\nName: G. Eric Davis\n\n \n\n \n\nTitle: President"}